首页> 外文OA文献 >Statin therapy and risks for death and hospitalization in chronic heart failure.
【2h】

Statin therapy and risks for death and hospitalization in chronic heart failure.

机译:他汀类药物治疗和慢性心力衰竭死亡和住院的风险。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

CONTEXT: Whether statin therapy has beneficial effects on clinical outcomes in patients with heart failure is unclear.OBJECTIVE: To evaluate the association between initiation of statin therapy and risks for death and hospitalization among adults with chronic heart failure.DESIGN, SETTING, AND PATIENTS: Propensity-adjusted cohort study of adults diagnosed with heart failure who were eligible for lipid-lowering therapy but had no previous known statin use, within an integrated health care delivery system in northern California between January 1, 1996, and December 31, 2004. Statin use was estimated from filled outpatient prescriptions in pharmacy databases.MAIN OUTCOME MEASURES: All-cause death and hospitalization for heart failure during a median of 2.4 years of follow-up. We examined the independent relationships between statin therapy and risks for adverse events overall and stratified by the presence or absence of coronary heart disease after multivariable adjustment for potential confounders.RESULTS: Among 24,598 adults diagnosed with heart failure who had no prior statin use, those initiating statin therapy (n = 12,648; 51.4%) were more likely to be younger, male, and have known cardiovascular disease, diabetes, and hypertension. There were 8235 patients who died. Using an intent-to-treat approach, incident statin use was associated with lower risks of death (age- and sex-adjusted rate of 14.5 per 100 person-years with statin therapy vs 25.3 per 100 person-years without statin therapy; adjusted hazard ratio, 0.76 [95% confidence interval, 0.72-0.80]) and hospitalization for heart failure (age- and sex-adjusted rate of 21.9 per 100 person-years with statin therapy vs 31.1 per 100 person-years without statin therapy; adjusted hazard ratio, 0.79 [95% confidence interval, 0.74-0.85]) even after adjustment for the propensity to take statins, cholesterol level, use of other cardiovascular medications, and other potential confounders. Incident statin use was associated with lower adjusted risks of adverse outcomes in patients with or without known coronary heart disease.CONCLUSION: Among adults diagnosed with heart failure who had no prior statin use, incident statin use was independently associated with lower risks of death and hospitalization among patients with or without coronary heart disease.
机译:背景:他汀类药物治疗对心力衰竭患者的临床结局是否有有益的作用尚不清楚。目的:评估他汀类药物治疗的开始与慢性心力衰竭成年人死亡和住院风险之间的关系。设计,地点和患者:在1996年1月1日至2004年12月31日之间,在加利福尼亚州北部的综合医疗服务提供系统中,对经过诊断的心力衰竭但有资格进行降脂治疗但以前没有使用他汀类药物的成年人进行了倾向性调整的队列研究。主要观察指标:在2.4年的中位随访期间,因心衰导致的全因死亡和住院治疗是主要的观察指标。我们检查了他汀类药物治疗与总体不良事件风险之间的独立关系,并通过对潜在混杂因素进行多变量调整后按是否存在冠心病进行了分层。结果:在24598名被诊断患有心力衰竭的成年人中,他们以前没有使用他汀类药物,他汀类药物治疗(n = 12,648; 51.4%)更有可能是年轻,男性,并且患有心血管疾病,糖尿病和高血压。有8235例患者死亡。使用意向性治疗方法,使用他汀类药物可降低死亡风险(接受他汀类药物治疗的按年龄和性别调整的比率为每100人年14.5,而没有他汀类药物治疗的比率为每100人年25.3;调整的危害比率,0.76 [95%置信区间,0.72-0.80])和心力衰竭住院治疗(年龄和性别调整率,他汀类药物治疗为每100人年21.9人,非他汀类药物治疗为每100人年31.1人;经调整的危险比率,即0.79 [95%置信区间,0.74-0.85]),即使在调整他汀类药物的服用倾向,胆固醇水平,使用其他心血管药物和其他潜在混杂因素之后也是如此。结论:在未曾使用他汀类药物的确诊为心力衰竭的成年人中,使用他汀类药物与死亡和住院的风险较低独立相关,在患有或未患有已知冠心病的患者中,他汀类药物的使用具有较低的不良后果调整风险。在有或没有冠心病的患者中。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号